BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32101529)

  • 1. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors.
    Castellnou S; Vasiljevic A; Lapras V; Raverot V; Alix E; Borson-Chazot F; Jouanneau E; Raverot G; Lasolle H
    Endocr Connect; 2020 Feb; 9(3):243-53. PubMed ID: 32101529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.
    Perez-Rivas LG; Theodoropoulou M; Ferraù F; Nusser C; Kawaguchi K; Stratakis CA; Faucz FR; Wildemberg LE; Assié G; Beschorner R; Dimopoulou C; Buchfelder M; Popovic V; Berr CM; Tóth M; Ardisasmita AI; Honegger J; Bertherat J; Gadelha MR; Beuschlein F; Stalla G; Komada M; Korbonits M; Reincke M
    J Clin Endocrinol Metab; 2015 Jul; 100(7):E997-1004. PubMed ID: 25942478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential microRNA Expression in
    Bujko M; Kober P; Boresowicz J; Rusetska N; Zeber-Lubecka N; Paziewska A; Pekul M; Zielinski G; Styk A; Kunicki J; Ostrowski J; Siedlecki JA; Maksymowicz M
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33498176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
    Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
    Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro.
    Albani A; Perez-Rivas LG; Tang S; Simon J; Lucia KE; Colón-Bolea P; Schopohl J; Roeber S; Buchfelder M; Rotermund R; Flitsch J; Thorsteinsdottir J; Herms J; Stalla G; Reincke M; Theodoropoulou M
    Endocr Relat Cancer; 2022 Aug; 29(8):503-511. PubMed ID: 35686696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
    Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
    Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.
    Uzilov AV; Taik P; Cheesman KC; Javanmard P; Ying K; Roehnelt A; Wang H; Fink MY; Lau CY; Moe AS; Villar J; Bederson JB; Stewart AF; Donovan MJ; Mahajan M; Sebra R; Post KD; Chen R; Geer EB
    J Clin Endocrinol Metab; 2021 Mar; 106(3):826-842. PubMed ID: 33221858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic
    Pérez-Rivas LG; Theodoropoulou M; Puar TH; Fazel J; Stieg MR; Ferraù F; Assié G; Gadelha MR; Deutschbein T; Fragoso MC; Kusters B; Saeger W; Honegger J; Buchfelder M; Korbonits M; Bertherat J; Stalla GK; Hermus AR; Beuschlein F; Reincke M
    Eur J Endocrinol; 2018 Jan; 178(1):57-63. PubMed ID: 28982703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status.
    Bujko M; Kober P; Boresowicz J; Rusetska N; Paziewska A; Dąbrowska M; Piaścik A; Pękul M; Zieliński G; Kunicki J; Bonicki W; Ostrowski J; Siedlecki JA; Maksymowicz M
    Eur J Endocrinol; 2019 Dec; 181(6):615-627. PubMed ID: 31581124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.
    Treppiedi D; Marra G; Di Muro G; Esposito E; Barbieri AM; Catalano R; Mangili F; Bravi F; Locatelli M; Lania AG; Ferrante E; Indirli R; Nozza E; Arlati F; Spada A; Arosio M; Mantovani G; Peverelli E
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
    Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
    Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
    Gatto F; Arvigo M; Ferone D
    J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cushing's disease due to somatic USP8 mutations: a systematic review and meta-analysis.
    Wanichi IQ; de Paula Mariani BM; Frassetto FP; Siqueira SAC; de Castro Musolino NR; Cunha-Neto MBC; Ochman G; Cescato VAS; Machado MC; Trarbach EB; Bronstein MD; Fragoso MCBV
    Pituitary; 2019 Aug; 22(4):435-442. PubMed ID: 31273566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The USP8 mutational status may predict long-term remission in patients with Cushing's disease.
    Albani A; Pérez-Rivas LG; Dimopoulou C; Zopp S; Colón-Bolea P; Roeber S; Honegger J; Flitsch J; Rachinger W; Buchfelder M; Stalla GK; Herms J; Reincke M; Theodoropoulou M
    Clin Endocrinol (Oxf); 2018 Jun; ():. PubMed ID: 29957855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas.
    Losa M; Mortini P; Pagnano A; Detomas M; Cassarino MF; Pecori Giraldi F
    Endocrine; 2019 Feb; 63(2):240-246. PubMed ID: 30315484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas.
    Sbiera S; Tryfonidou MA; Weigand I; Grinwis GC; Broeckx B; Herterich S; Allolio B; Deutschbein T; Fassnacht M; Meij BP
    PLoS One; 2016; 11(12):e0169009. PubMed ID: 28005997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease.
    Rebollar-Vega RG; Zuarth-Vázquez JM; Hernández-Ramírez LC
    Arch Med Res; 2023 Dec; 54(8):102899. PubMed ID: 37925320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic USP8 alteration affects the immune landscape of corticotroph pituitary adenomas- a pilot study.
    Greidinger D; Halperin R; Zemet R; Maixner N; Tirosh A
    Hormones (Athens); 2024 May; ():. PubMed ID: 38819743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.